Business Wire

Arcserve Announces Appointment of Brannon Lacey as Chief Executive Officer

Share

Arcserve, the world's most experienced data and ransomware protection provider, today announced the appointment of Brannon Lacey as its CEO, effective immediately. A twenty-year veteran of the technology industry, Lacey brings extensive experience and success in building high-performance global software, cloud, cyber security, and infrastructure organizations.

The appointment comes as Arcserve is poised to rapidly expand on its global top 5 data protection vendor position following the merger with StorageCraft in March of this year. Arcserve brings much-needed data and business certainty to organizations of all sizes globally through the broadest set of best-in-class business continuity solutions.

Said Dave Hansen, Arcserve's Chairman of the Board: "Brannon is an exceptional business leader. He brings a tremendous track record in leading fast-growth global companies and achieving strong and sustainable growth in highly competitive markets. His deep experience with channel-driven organizations from both vendor and customer perspective will be of immense value to Arcserve as a 100% channel-centric company."

Adds Brannon Lacey, Arcserve CEO: "Arcserve commands an enormous market opportunity. It has best-in-world people, leadership, technologies, partners, and investors. I am excited and proud to take the leadership of Arcserve as we invest and focus on aggressive and sustainable global market growth."

Lacey joins Arcserve from PeopleScout, the world's largest Recruitment Process Outsourcing firm, where he served as president and oversaw the organizations' rapid digital transformation and growth. Previous roles include president of Benefits Solutions, a $2 billion business segment of human capital provider Alight; global SVP & general manager of Application Services with Rackspace, one of the world's largest managed services providers, and principal at Samsung Ventures, where he was responsible for venture capital investments in the mobility space.

Lacey is a graduate of the University of Arizona and earned his M.B.A. from Columbia Business School.

Dave Hansen, who served as interim CEO, will remain chairman of the Board at Arcserve.

Follow Arcserve on LinkedIn or Twitter, and read our latest data protection and management thought leadership articles on the Arcserve Blog.

About Arcserve

Arcserve, a global top 5 data protection vendor, provides the broadest set of best-in-class solutions to manage, protect and recover all data workloads, from SMB to enterprise and regardless of location or complexity. Arcserve solutions eliminate complexity while bringing best-in-class, cost-effective, agile, and massively scalable data protection and certainty across all data environments. This includes on-prem, off-prem (including DRaaS, BaaS, and Cloud-to-Cloud), hyperconverged, and edge infrastructures. The company's nearly three decades of award-winning IP, plus a continuous focus on innovation, means that partners and customers, including MSPs, VARs, LARs, and end-users, are assured of the fastest route to next-generation data workloads and infrastructures. A 100% channel-centric organization, Arcserve has a presence in over 150 countries, with 19,000 channel partners helping to protect 235,000 customers' critical data assets. Explore more at arcserve.com and follow @Arcserve on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jock Breitwieser
Arcserve
+1 408.800.5625
jock.breitwieser@arcserve.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

X-Chem Acquires ComInnex25.10.2021 20:00:00 CEST | Press release

X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery. With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market. “As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark, Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help bio

European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-1925.10.2021 16:30:00 CEST | Press release

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.1,2 “We are gratified the European Commission has recognized the potential of lenzilumab to offer an important treatment option for patients hospitalized with COVID-19,” said Cameron Durrant, MD, Chairman and CEO, Humanigen. “We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19. We are also progressing with our early access program, under compassionate use, where allowed by regulations in some European countries and the United States.” *Lenzilumab is not authorized, or approved

Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma25.10.2021 14:00:00 CEST | Press release

EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/ Standard Color Vision and Color Blind View @EnChroma In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering

Rockefeller Capital Management to Open First International Office in London with the Formation of Rockefeller Asset Management International25.10.2021 14:00:00 CEST | Press release

Rockefeller Asset Management (RAM), a division of Rockefeller Capital Management, with a long track record of investing in global equities and ESG investing has announced the formation of Rockefeller Asset Management International, to expand its European market presence. The initial plans for expansion include opening an office in London, to better serve clients across the UK, Europe, and Asia. “Our Asset Management business has generated real momentum across Europe and we are excited to continue to serve our international clients with a full suite of sustainable investment products and a growing local presence,” said Greg Fleming, CEO and President of Rockefeller Capital Management. RAM, which was recently awarded the 2021 Principles for Responsible Investing (PRI) award for “ESG incorporation initiative of the year,” has seen strong growth in Europe. Over the last two years, the business, which surpassed $2.5 billion in assets from European investors, launched a UCITS ICAV, an Irelan

Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 202125.10.2021 14:00:00 CEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis evaluated the safety and efficacy of investigational RBX2660 among a broad cohort of CDI patients with comorbidities commonly found in patients with CDI, and was recognized with a Presidential Poster Award for high-quality, novel, unique and interesting research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005099/en/ Ferring Fact Sheet While the eligibility criteria in prospective clinical trials often are narrowly defined to include patients diagnosed with only CDI, this analysis allowed researchers to evaluate the impact of RBX2660 in a patient population that is more reflective of a real-world setting. In the analysis, 94 participants with comorbid conditions commonly found in people with recurrent CDI (rCDI) were trea

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention25.10.2021 13:53:00 CEST | Press release

Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden. CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is t

Everbridge Awarded Contract to Power Countrywide Public Warning System in The Netherlands25.10.2021 13:30:00 CEST | Press release

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced that the Netherlands selected the company’s end-to-end countrywide Public Warning solution to help keep its residents and visitors safe and informed in the event of an emergency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005296/en/ Everbridge Awarded Contract to Power Countrywide Public Warning System in The Netherlands (Photo: Business Wire) One of the most densely populated regions in Europe, 17.5 million residents call the Netherlands home, and millions of tourists visit the coastal country each year. Powered by Everbridge, NL-Alert can reach 94 percent of the Dutch population on their mobile phones, along with digital signage at bus, train, tram, and metro stations across the country. The Netherlands will leverage Everbridge’s next-generation, end-to-end Public Warning solution, featuring a unique multi-chann

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom